Pseudoephedrine/loratadine

Pseudoephedrine/loratadine

Combination of
Pseudoephedrine	Sympathomimetic
Loratadine	H1 antagonist
Clinical data
Pregnancy cat.	B(US)
Legal status	OTC
Routes	Oral
Identifiers
ATC code	R01BA52
Y(what is this?)  (verify)

Pseudoephedrine/loratadine (trade names Claritin-D, Clarinase, Clarinase Repetabs) is an orally administered drug combination for the treatment of allergic rhinitis and the common cold. Pseudoephedrine, one of the naturally occurring alkaloids of ephedra, is a sympathomimetic used as a decongestant. It produces its decongestant effect facilitating vasoconstriction and shrinkage of congested mucosa in upper respiratory areas. Loratadine is a long acting H₁ histamine antagonist that is less sedating than older substances of the type.

Indications and usage

Clarinase repetabs tablets are indicated for the relief of symptoms associated with allergic rhinitis and the common cold including nasal congestion, sneezing, rhinorrhea, pruritus and lacrimation.

Composition

Clarinase Repetabs

A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.

Interactions, adverse effects and contraindications

Interactions, adverse effects and contraindications are described in more detail in the articles about pseudoephedrine and loratadine.

Interactions

When sympathomimetics are given to patients receiving monoamine oxidase inhibitors (MAO inhibitors), hypertensive reactions, including hypertensive crises may occur.

Adverse effects

During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported.

Contraindications

Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism.

References

• Drugs.com: Claritin-D
• Israel Ministry of Health: Clarinase Repetabs
• Haberfeld, H, ed (2009) (in German). Austria-Codex (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.